Toronto Western Hospital

Running trials

• Recruiting

  A Post Authorization Registry Study of Participants Treated With LEQEMBI

  NCT07762092· Source

• Recruiting

  Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

  NCT07569198· Phase 2· Source

• Enrolling by invitation

  Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

  NCT07737990· Source

• Recruiting

  Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

  NCT07245732· Phase 4· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

  NCT07234942· Phase 1· Source

• Recruiting

  Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

  NCT07107022· Source

• Recruiting

  Levetiracetam for Persons at Risk for Alzheimer's Disease

  NCT07477431· Phase 2· Source

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  Deep Brain Stimulation of the Pedunculopontine Nucleus for Alzheimer's Disease

  NCT06936124· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Source

• Not yet recruiting

  Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance

  NCT05703360· Source

• Recruiting

  Pedunculopontine Nucleus Transcranial Ultrasound Stimulation as a Treatment of Freezing of Gait in Parkinson's Disease

  NCT07695233· Source

• Recruiting

  Effects of Excitatory and Inhibitory LIFUS of GPi in Parkinsonian Patients Without DBS

  NCT07846007· Source

• Active, not recruiting

  Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

  NCT06341426· Phase 2· Source

• Recruiting

  Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

  NCT07265596· Phase 2· Source

• Active, not recruiting

  Towards Noninvasive DBS of the Basal Ganglia in Parkinson's Disease Using TUS

  NCT06232629· Source

• Enrolling by invitation

  Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

  NCT05897957· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Source

• Recruiting

  Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

  NCT05306899· Phase 3· Source

• Recruiting

  Biofeedback for Hemianopia Vision Rehabilitation

  NCT05397873· Source

• Recruiting

  Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

  NCT04973397· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· Phase 2· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Source

• Recruiting

  PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

  NCT04477785· Source

• Recruiting

  Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

  NCT03474029· Phase 2/3· Source

• Active, not recruiting

  ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

  NCT03319485· Source

• Active, not recruiting

  Multicenter Phase II Study of Transanal TME (taTME)

  NCT03144765· Source

• Active, not recruiting

  ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

  NCT02252380· Source

• Recruiting

  Canadian Fabry Disease Initiative (CFDI) National Registry

  NCT00455104· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease6 recruiting
• Alzheimer disease4 recruiting
• Stroke3 recruiting
• Depression2 recruiting
• Lupus (SLE)2 recruiting
• Bipolar disorder1 recruiting
• Coronary artery disease1 recruiting
• Fabry disease1 recruiting
• Migraine1 recruiting
• Rheumatoid arthritis1 recruiting
• Tuberculosis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy/Seizure-Specific Interictal Anxiety

  NCT06028945· Source

• Terminated

  Fenfluramine for Adult Dravet Patients

  NCT05560282· Phase 3· Source

• Completed

  Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

  NCT05339074· Phase 2· Source

• Completed

  Ketamine for Treatment-Resistant Bipolar Disorder

  NCT05004896· Phase 2· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Source

• Completed

  Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

  NCT04466345· Phase 2· Source

• Completed

  Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

  NCT04802733· Phase 1· Source

• Completed

  Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease

  NCT04547712· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Source

• Completed

  Tele-CBT Following Bariatric Surgery: Randomized Control Trial

  NCT03315247· Source

• Recruiting

  Primary Tumor Research and Outcomes Network

  NCT02790983· Source